Growing up witnessing the devastating effects of HIV in her family and community in South Africa pushed Olwam Plaatjie to start using preventive HIV medications three years ago. The 19-year-old is one of thousands of South Africans who signed up for clinical trials of lenacapavir, a highly effective, twice-yearly injectable prevention drug that addresses the drawbacks of daily oral prevention pills.